Payment overview · 2025
General Payments
$192.27
9 reported records · 8 companies
Healthcare provider profile · identity verified
Kashif Naseem, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AUGUSTA, GA · NPI 1699762054
Verified facts
What the public records show
CMS Open Payments records show Kashif Naseem, MD received $192.27 in general payments during 2025 across 9 reported records.
SHIELD THERAPEUTICS INC accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.44 | 17.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.98 | 17.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.46 | 13.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.22 | 11.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.84 | 10.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.38 | 10.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.94 | 9.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.01 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $192.27 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1474 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 1074 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 636 | 136 |
| Gabapentin | Gabapentin | 631 | 129 |
| Donepezil Hcl | Donepezil Hcl | 618 | 95 |
| Quetiapine Fumarate | Quetiapine Fumarate | 566 | 71 |
| Lisinopril | Lisinopril | 520 | 92 |
| Sertraline Hcl | Sertraline Hcl | 519 | 75 |
| Trazodone Hcl | Trazodone Hcl | 507 | 89 |
| Furosemide | Furosemide | 489 | 93 |
| Metformin Hcl | Metformin Hcl | 480 | 89 |
| Losartan Potassium | Losartan Potassium | 472 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 449 | 76 |
| Potassium Chloride | Potassium Chloride | 391 | 75 |
| Famotidine | Famotidine | 388 | 75 |
| Carvedilol | Carvedilol | 371 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 333 | 70 |
| Memantine Hcl | Memantine Hcl | 323 | 41 |
| Eliquis | Apixaban | 322 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 282 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 60 |
| Risperidone | Risperidone | 250 | 33 |
| Omeprazole | Omeprazole | 229 | 59 |
| Olanzapine | Olanzapine | 224 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 90 |
| Montelukast Sodium | Montelukast Sodium | 222 | 39 |
| Levetiracetam | Levetiracetam | 209 | 41 |
| Mirtazapine | Mirtazapine | 205 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 34 |
| Glipizide | Glipizide | 174 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 170 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 33 |
| Buspirone Hcl | Buspirone Hcl | 160 | 37 |
| Finasteride | Finasteride | 158 | 30 |
| Simvastatin | Simvastatin | 156 | 26 |
| Meloxicam | Meloxicam | 155 | 34 |
| Aripiprazole | Aripiprazole | 151 | 22 |
| Glipizide Er | Glipizide | 151 | 31 |
| Tramadol Hcl | Tramadol Hcl | 151 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 43 |
| Spironolactone | Spironolactone | 143 | 27 |
| Metformin Hcl Er | Metformin Hcl | 132 | 23 |
| Januvia | Sitagliptin Phosphate | 128 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 21 |
| Allopurinol | Allopurinol | 122 | 28 |
| Divalproex Sodium | Divalproex Sodium | 113 | 14 |
| Methocarbamol | Methocarbamol | 113 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 26 |
| Clonazepam | Clonazepam | 106 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 103 | suppressed |
| Alprazolam | Alprazolam | 98 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 92 | 12 |
| Chlorthalidone | Chlorthalidone | 91 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 90 | 18 |
| Jardiance | Empagliflozin | 89 | 14 |
| Propranolol Hcl | Propranolol Hcl | 89 | 14 |
| Baclofen | Baclofen | 84 | 17 |
| Alendronate Sodium | Alendronate Sodium | 83 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 19 |
| Bupropion Xl | Bupropion Hcl | 81 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 20 |
| Ozempic | Semaglutide | 75 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 75 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 74 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 17 |
| Valsartan | Valsartan | 71 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 19 |
| Farxiga | Dapagliflozin Propanediol | 70 | 15 |
| Naproxen | Naproxen | 69 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | suppressed |
| Haloperidol | Haloperidol | 67 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 14 |
| Linzess | Linaclotide | 66 | 13 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Azithromycin | Azithromycin | 64 | 60 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 15 |
| Atenolol | Atenolol | 63 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Ketoconazole | Ketoconazole | 62 | 14 |
| Megestrol Acetate | Megestrol Acetate | 62 | 15 |
| Midodrine Hcl | Midodrine Hcl | 62 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 12 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Celecoxib | Celecoxib | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 14 |
| Ibuprofen | Ibuprofen | 56 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 55 | suppressed |
| Prednisone | Prednisone | 53 | 27 |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 22 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 49 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Meclizine Hcl | Meclizine Hcl | 47 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 27 |
| Scopolamine | Scopolamine | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 46 | suppressed |
| Sucralfate | Sucralfate | 45 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Primidone | Primidone | 44 | suppressed |
| Ramipril | Ramipril | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | 13 |
| Loperamide | Loperamide Hcl | 41 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 21 |
| Constulose | Lactulose | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 12 |
| Torsemide | Torsemide | 36 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 14 |
| Lacosamide | Lacosamide | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 30 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 28 |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 11 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 24 |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Pancreaze | Lipase/Protease/Amylase | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nystatin | Nystatin | 15 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Isoniazid | Isoniazid | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.27 · 9 records | SHIELD THERAPEUTICS INC | ACCRUFER, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, Ozempic, TRELEGY ELLIPTA, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error